{"generic":"Cysteamine Bitartrate","drugs":["Cystagon","Cysteamine Bitartrate","Procysbi"],"mono":{"0":{"id":"922404-s-0","title":"Generic Names","mono":"Cysteamine Bitartrate"},"1":{"id":"922404-s-1","title":"Dosing and Indications","sub":{"0":{"id":"922404-s-1-4","title":"Adult Dosing","mono":"<ul><li><b>Cystinosis, Nephropathic:<\/b> (immediate-release) initial, one-quarter to one-sixth of maintenance dose ORALLY; slowly increase dose over 4 to 6 weeks to maintenance dose of 2 g\/day ORALLY in 4 divided doses<\/li><li><b>Cystinosis, Nephropathic:<\/b> (delayed-release) initial, one-sixth to one-quarter of maintenance dose ORALLY; slowly increase dose over 4 to 6 weeks to maintenance dose of 1.3 g\/m(2)\/day ORALLY in 2 divided doses administered every 12 hours; MAX dose, 1.95 g\/m(2)\/day<\/li><li><b>Cystinosis, Nephropathic:<\/b> (delayed-release) conversion from immediate release, administer total daily dose of immediate-release cysteamine ORALLY in 2 divided doses 12 hours apart<\/li><\/ul>"},"1":{"id":"922404-s-1-5","title":"Pediatric Dosing","mono":"<ul><li>(delayed-release) safety and efficacy not established in children younger than 6 years<\/li><li><b>Cystinosis, Nephropathic:<\/b> (immediate-release) initial, one-quarter to one-sixth of maintenance dose ORALLY; slowly increase over 4 to 6 weeks to maintenance dose of 1.3 g\/m(2)\/day ORALLY in 4 divided doses (age up to 12 years) or 2 g\/day in 4 divided doses (age over 12 years and 110 pounds (55 kg))<\/li><li><b>Cystinosis, Nephropathic:<\/b> (delayed-release) 6 years or older, initial, one-sixth to one-quarter of maintenance dose ORALLY; slowly increase dose over 4 to 6 weeks to maintenance dose of 1.3 g\/m(2)\/day ORALLY in 2 divided doses administered every 12 hours; MAX dose, 1.95 g\/m(2)\/day<\/li><li><b>Cystinosis, Nephropathic:<\/b> (delayed-release) 6 years or older, conversion from immediate release, administer total daily dose of immediate-release cysteamine ORALLY in 2 divided doses 12 hours apart<\/li><\/ul>"},"3":{"id":"922404-s-1-7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><br\/>Cystinosis, Nephropathic<br\/>"}}},"3":{"id":"922404-s-3","title":"Contraindications\/Warnings","sub":[{"id":"922404-s-3-9","title":"Contraindications","mono":"hypersensitivity to penicillamine  or cysteamine <br\/>"},{"id":"922404-s-3-10","title":"Precautions","mono":"<ul><li>benign intracranial hypertension (pseudotumor cerebri), with or without papilledema, may occur; monitoring recommended<\/li><li>CNS symptoms, including lethargy, somnolence, and depression, may occur; monitoring recommended; interruption of therapy or dose reductions may be warranted<\/li><li>encephalopathy may occur; monitoring recommended; interruption of therapy or dose reductions may be warranted<\/li><li>gastrointestinal bleeding and ulceration may occur<\/li><li>gastrointestinal tract adverse effects, including nausea, vomiting, anorexia, and abdominal pain, may occur; interruption of therapy  or dose adjustment may be necessary with severe symptoms<\/li><li>leukopenia may occur; monitoring recommended<\/li><li>liver function test abnormalities, particularly elevations of alkaline phosphatase, may occur; monitoring recommended<\/li><li>papilledema may occur; monitoring recommended<\/li><li>seizures may occur; monitoring recommended; interruption of therapy or dose reductions may be warranted<\/li><li>skin and bone lesions (ie, molluscoid pseudotumors, skin striae, osteopenia, compression fractures, scoliosis, genu valgum) with joint hyperextension and leg pain, resembling clinical features of Ehler-Danlos syndrome, may occur; increased risk with high doses; monitoring recommended; therapy interruption  and dose adjustment recommended<\/li><li>skin rash, severe, including erythema multiforme bullosa and toxic epidermal necrolysis, may occur; permanently discontinue use<\/li><li>skin rashes may occur; therapy interruption and dose adjustment recommended<\/li><\/ul>"},{"id":"922404-s-3-11","title":"Pregnancy Category","mono":"<ul><li>Cysteamine: C (FDA)<\/li><li>Cysteamine: B3 (AUS)<\/li><\/ul>"},{"id":"922404-s-3-12","title":"Breast Feeding","mono":"Cysteamine: Micromedex: Infant risk cannot be ruled out.<br\/>"}]},"5":{"id":"922404-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Dermatologic:<\/b>Finding of odor of skin (delayed-release, at least 5%), Rash (immediate-release, 7%; delayed release, at least 5%)<\/li><li><b>Gastrointestinal:<\/b>Abdominal pain (delayed-release, 14%), Breath smells unpleasant (delayed-release, at least 5%), Diarrhea (immediate release, 16%; delayed-release, at least 5%), Loss of appetite (immediate-release, 5% to 31%; delayed-release, 2% to greater than or equal to 5%), Nausea (immediate-release, up to 7%; delayed-release, up to 16%), Vomiting (immediate-release, 12% to 35%; delayed-release, up to 19%)<\/li><li><b>Neurologic:<\/b>Dizziness (delayed-release, 5% or greater), Headache (delayed-release, up to 9%), Lethargy (immediate-release, 11%)<\/li><li><b>Other:<\/b>Fever (immediate-release, 22%)<\/li><\/ul><b>Serious<\/b><ul><li><b>Dermatologic:<\/b>Erythema multiforme, Skin lesion, Skin striae, Toxic epidermal necrolysis<\/li><li><b>Gastrointestinal:<\/b>Gastrointestinal hemorrhage, Gastrointestinal ulcer<\/li><li><b>Hematologic:<\/b>Leukopenia<\/li><li><b>Musculoskeletal:<\/b>Fracture of bone, Hyperextension, Osteopenia, Pain in lower limb, Scoliosis deformity of spine<\/li><li><b>Neurologic:<\/b>CNS symptom, Encephalopathy, Pseudotumor cerebri, Seizure, Somnolence<\/li><li><b>Ophthalmic:<\/b>Papilledema - optic disc edema due to raised intracranial pressure<\/li><\/ul>"},"6":{"id":"922404-s-6","title":"Drug Name Info","sub":{"0":{"id":"922404-s-6-17","title":"US Trade Names","mono":"<ul><li>Cystagon<\/li><li>Procysbi<\/li><\/ul>"},"2":{"id":"922404-s-6-19","title":"Class","mono":"Renal-Urologic Agent<br\/>"},"3":{"id":"922404-s-6-20","title":"Regulatory Status","mono":"RX<br\/>"},"4":{"id":"922404-s-6-21","title":"Generic Availability","mono":"No<br\/>"}}},"7":{"id":"922404-s-7","title":"Mechanism Of Action","mono":"Cysteamine bitartrate is a cystine depleting agent which reduces the cystine content of cells in cystinotic patients. It takes part in a thiol-disulfide interchange reaction within lysosomes as it converts cystine into cysteine and cysteine-cysteamine mixed disulfide, both of which can exit the lysosome in cystinotic patients.<br\/>"},"8":{"id":"922404-s-8","title":"Pharmacokinetics","sub":{"0":{"id":"922404-s-8-23","title":"Absorption","mono":"<ul><li>Tmax, Oral, delayed-release: 2.78 hours:<\/li><li>Tmax, Oral, immediate-release: 1.4 hours<\/li><li>Effect of food, delayed-release: reduced systemic exposure<\/li><\/ul>"},"1":{"id":"922404-s-8-24","title":"Distribution","mono":"<ul><li>Vd: 156 L<\/li><li>Protein binding: 52%<\/li><\/ul>"},"3":{"id":"922404-s-8-26","title":"Excretion","mono":"Plasma clearance: 1.2 L\/min <br\/>"}}},"9":{"id":"922404-s-9","title":"Administration","mono":"<b>Oral<\/b><br\/><ul><li>(immediate-release) do not administer intact capsules to children under the age of approximately 6 years due to risk of aspiration; may administer by sprinkling capsule contents over food<\/li><li>(delayed-release) administer at least 30 minutes before and 2 hours after meals; if necessary, 4 ounces (one-half cup) of food may be eaten 1 hour before and 1 hour after administration<\/li><li>(delayed-release) swallow capsules whole; do not crush or chew<\/li><li>(delayed-release) capsules may be opened and granules sprinkled on 4 ounces apple sauce or berry jelly, or mixed with 4 ounces of orange or apple juice<\/li><li>(delayed-release) may be administered via gastrostomy tube 12 French or larger by sprinkling granules on 4 ounces of applesauce, then flushing tube with 8 ounces orange or apple juice<\/li><li>take food or juice mixture within 30 minutes of preparation<\/li><\/ul>"},"10":{"id":"922404-s-10","title":"Monitoring","mono":"<ul><li>leukocyte cystine levels; at least every 3 months (immediate-release); monthly for 3 months then quarterly for 12 months, then at least twice per year, in cysteamine-naive patients (delayed-release); every 2 weeks then quarterly for 6 months then at least twice yearly, in patients switching from immediate-release (delayed-release)<\/li><li>serum creatinine and electrolytes, 24-hour urinary protein, creatinine clearance<\/li><li>physical examination for body weight and growth velocity; every 4 months<\/li><li>ophthalmological examination<\/li><li>alkaline phosphatase<\/li><li>blood counts<\/li><li>hepatic function<\/li><li>skin or bone lesions<\/li><li>gastrointestinal bleeding or ulceration signs and symptoms<\/li><li>symptoms of benign intracranial hypertension (pseudotumor cerebri) and\/or papilledema; headache, tinnitus, dizziness, nausea, diplopia, blurry vision, loss of vision, pain behind the eye, or pain with eye movement<\/li><li>signs of serious skin rash<\/li><\/ul>"},"11":{"id":"922404-s-11","title":"How Supplied","mono":"<ul><li><b>Cystagon<\/b><br\/>Oral Capsule: 50 MG, 150 MG<br\/><\/li><li><b>Procysbi<\/b><br\/>Oral Capsule, Delayed Release: 25 MG, 75 MG<br\/><\/li><\/ul>"},"13":{"id":"922404-s-13","title":"Clinical Teaching","mono":"<ul><li>Advise patient to avoid activities requiring mental alertness or coordination until drug effects are realized, as drug may cause dizziness, lethargy, or somnolence.<\/li><li>Tell patient to immediately report symptoms of benign intracranial hypertension (ie, headaches, tinnitus, nausea, diplopia, blurred or loss of vision, eye pain).<\/li><li>Counsel patient to report CNS symptoms such as seizures, depression, and encephalopathy.<\/li><li>Drug may cause abdominal pain, anorexia, diarrhea, nausea, vomiting, or headaches.<\/li><li>Warn patient to report symptoms of erythema multiforme or toxic epidermal necrolysis.<\/li><li>Instruct patient to immediately report symptoms of gastrointestinal ulcers or bleeding.<\/li><li>Counsel patient to take delayed-release capsule at least 2 hours after and 30 minutes before a meal. If needed, patient can consume 4 ounces of food 1 hour before or after dose. Take consistently with regard to food and avoid high-fat foods close to dosing.<\/li><li>Advise caregiver of child younger than 6 years of age to open immediate-release capsule and sprinkle contents over food.<\/li><li>Instruct patient taking the immediate-release capsule to take a missed dose as soon as possible. If the next dose is within 2 hours, skip the missed dose and resume a regular schedule.<\/li><li>Advise patient taking the delayed-release capsule to take a missed dose as soon as possible. If the next dose is within 4 hours, skip the missed dose and resume a regular schedule.<\/li><\/ul>"}}}